Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Depreciation & Amortization (CF): 2022-2025

Historic Depreciation & Amortization (CF) for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $120,000.

  • Axsome Therapeutics' Depreciation & Amortization (CF) fell 8.40% to $120,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $518,000, marking a year-over-year decrease of 3.36%. This contributed to the annual value of $532,000 for FY2024, which is 15.90% up from last year.
  • Per Axsome Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $120,000 for Q3 2025, which was down 0.00% from $120,000 recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $149,000 for Q1 2025, and its period low was $37,000 during Q1 2022.
  • For the 3-year period, Axsome Therapeutics' Depreciation & Amortization (CF) averaged around $125,455, with its median value being $131,000 (2024).
  • As far as peak fluctuations go, Axsome Therapeutics' Depreciation & Amortization (CF) surged by 143.24% in 2023, and later declined by 14.29% in 2025.
  • Quarterly analysis of 4 years shows Axsome Therapeutics' Depreciation & Amortization (CF) stood at $85,000 in 2022, then surged by 56.47% to $133,000 in 2023, then declined by 3.01% to $129,000 in 2024, then decreased by 8.40% to $120,000 in 2025.
  • Its Depreciation & Amortization (CF) was $120,000 in Q3 2025, compared to $120,000 in Q2 2025 and $149,000 in Q1 2025.